• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Revista Cubana de Hematología, Inmunología y Hemoterapia >Use of recombinant-activated factor VIIa as a hemostatic agent in hemorrhagic disorders
【24h】

Use of recombinant-activated factor VIIa as a hemostatic agent in hemorrhagic disorders

机译：重组激活的VIIa因子在出血性疾病中作为止血剂的用途

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Effectiveness of the treatment with recombinant activated factor VII (raVII) during the hemorrhagic episodes in hemophilic patients using inhibitions and the knowledge of its action mechanism determined that in pas years its use will be expanded in patients with hemorrhage from non-controlled diverse causes using the usual therapeutics among other, congenital coagulation defects, platelet disorders, liver diseases, surgery, intracranial hemorrhage, digestive bleedings. Although a significant group of these communications have been carried out in reported cases and in cases series, it is considered that the results obtained are important and that the administration of raVII is an alternative in patients presenting with non-controlled severe hemorrhage. Despite its potent pro-coagulant action, thromboembolism complications risk is low and it is related to a significant group of patients with other prothrombotic factors. Nowadays, it is considered that raVII is prescribed in those patients with massive hemorrhage without response either to therapy using blood components or appropriate surgical measures.
机译：使用抑制因子在血友病患者出血发作期间使用重组活化因子VII（raVII）进行治疗的有效性及其作用机制的知识确定，在过去几年中，由于非控制性多种原因的出血，使用该药物的患者将扩大其使用范围先天性凝血功能缺陷，血小板异常，肝脏疾病，手术，颅内出血，消化道出血等常见疗法。尽管在已报告的病例和病例系列中已经进行了大量此类交流，但是据认为获得的结果很重要，在患有不受控制的严重出血的患者中，使用raVII是替代方法。尽管具有有效的促凝血作用，但血栓栓塞并发症的风险较低，并且与大量具有其他血栓形成因素的患者有关。如今，人们认为对于那些有大量出血而对使用血液成分的治疗或适当的手术措施无反应的患者，开具了raVII。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号